Announcement • Jun 02
Liu Hongjun cancelled the acquisition of 10% stake in Dalian BIO-CHEM Company Limited (SHSE:603360) from Dalian Guangyao Zhixin Shuhong Enterprise Management Consulting Partnership Enterprise (L.P) and Dalian Tongyun Investment Co., Ltd. Liu Hongjun entered into share transfer agreement to acquire 10% stake in Dalian BIO-CHEM Company Limited (SHSE:603360) from Dalian Guangyao Zhixin Shuhong Enterprise Management Consulting Partnership Enterprise (L.P) and Dalian Tongyun Investment Co., Ltd. for approximately CNY 990 million on November 26, 2025. A cash consideration of CNY 992.81 million will be paid by the buyer. As part of consideration, CNY 992.81 million is paid towards common equity of Dalian BIO-CHEM Company Limited.
Liu Hongjun cancelled the acquisition of 10% stake in Dalian BIO-CHEM Company Limited (SHSE:603360) from Dalian Guangyao Zhixin Shuhong Enterprise Management Consulting Partnership Enterprise (L.P) and Dalian Tongyun Investment Co., Ltd. on May 31, 2026. Valuation Update With 7 Day Price Move • Jun 02
Investor sentiment deteriorates as stock falls 27% After last week's 27% share price decline to CN¥19.36, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 286% over the past three years. Announcement • Apr 30
Dalian BIO-CHEM Company Limited (SHSE:603360) announces an Equity Buyback for CNY 100 million worth of its shares. Dalian BIO-CHEM Company Limited (SHSE:603360) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its class A shares. The company will repurchase its shares at a price not more than CNY 38.32 per share. The repurchased shares will be used for Employee Stock Ownership Plan or Equity Incentive. The plan will be valid for 12 months. Reported Earnings • Apr 28
Full year 2025 earnings released: EPS: CN¥0.30 (vs CN¥0.49 in FY 2024) Full year 2025 results: EPS: CN¥0.30 (down from CN¥0.49 in FY 2024). Revenue: CN¥1.72b (up 31% from FY 2024). Net income: CN¥209.8m (down 39% from FY 2024). Profit margin: 12% (down from 26% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 56% per year, which means it is well ahead of earnings. Announcement • Apr 28
Dalian BIO-CHEM Company Limited, Annual General Meeting, May 18, 2026 Dalian BIO-CHEM Company Limited, Annual General Meeting, May 18, 2026, at 13:30 China Standard Time. Location: The Company's Meeting Room, Dalian, Liaoning China Announcement • Mar 30
Dalian BIO-CHEM Company Limited to Report Q1, 2026 Results on Apr 30, 2026 Dalian BIO-CHEM Company Limited announced that they will report Q1, 2026 results on Apr 30, 2026 Announcement • Dec 26
Dalian BIO-CHEM Company Limited to Report Fiscal Year 2025 Results on Apr 24, 2026 Dalian BIO-CHEM Company Limited announced that they will report fiscal year 2025 results on Apr 24, 2026 Reported Earnings • Nov 03
Third quarter 2025 earnings released: EPS: CN¥0.043 (vs CN¥0.13 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.043 (down from CN¥0.13 in 3Q 2024). Revenue: CN¥307.2m (down 1.8% from 3Q 2024). Net income: CN¥20.5m (down 77% from 3Q 2024). Profit margin: 6.7% (down from 29% in 3Q 2024). The decrease in margin was primarily driven by higher expenses. Revenue is expected to decline by 4.6% p.a. on average during the next 2 years, while revenues in the Chemicals industry in China are expected to grow by 16%. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 72% per year, which means it is well ahead of earnings. New Risk • Oct 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 116% Dividend per share is over 13x cash flows per share. Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Profit margins are more than 30% lower than last year (19% net profit margin). Announcement • Sep 30
Dalian BIO-CHEM Company Limited to Report Q3, 2025 Results on Oct 30, 2025 Dalian BIO-CHEM Company Limited announced that they will report Q3, 2025 results on Oct 30, 2025 Valuation Update With 7 Day Price Move • Aug 28
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥25.45, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 23x in the Chemicals industry in China. Total returns to shareholders of 378% over the past three years. Announcement • Jun 30
Dalian BIO-CHEM Company Limited to Report First Half, 2025 Results on Aug 29, 2025 Dalian BIO-CHEM Company Limited announced that they will report first half, 2025 results on Aug 29, 2025 Valuation Update With 7 Day Price Move • May 28
Investor sentiment deteriorates as stock falls 27% After last week's 27% share price decline to CN¥19.86, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 167% over the past three years. Declared Dividend • May 26
Dividend of CN¥0.60 announced Shareholders will receive a dividend of CN¥0.60. Ex-date: 29th May 2025 Payment date: 29th May 2025 Dividend yield will be 2.1%, which is lower than the industry average of 2.6%. Sustainability & Growth Dividend is not covered by earnings (102% earnings payout ratio) nor is it covered by cash flows (389% cash payout ratio). The dividend has increased by an average of 11% per year over the past 8 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 13% to bring the payout ratio under control. EPS is expected to grow by 18% over the next year, which is sufficient to bring the dividend into a sustainable range. New Risk • May 15
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 21% Last year net profit margin: 31% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 102% Cash payout ratio: 389% Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Profit margins are more than 30% lower than last year (21% net profit margin). New Risk • Apr 30
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 21% Last year net profit margin: 31% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (278% cash payout ratio). Share price has been volatile over the past 3 months (8.8% average weekly change). Profit margins are more than 30% lower than last year (21% net profit margin). Reported Earnings • Apr 25
Full year 2024 earnings: EPS in line with analyst expectations despite revenue beat Full year 2024 results: EPS: CN¥0.68 (up from CN¥0.66 in FY 2023). Revenue: CN¥1.31b (up 23% from FY 2023). Net income: CN¥345.3m (up 5.1% from FY 2023). Profit margin: 26% (down from 31% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to stay flat during the next 2 years compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 56% per year, which means it is well ahead of earnings. Announcement • Apr 25
Dalian BIO-CHEM Company Limited, Annual General Meeting, May 15, 2025 Dalian BIO-CHEM Company Limited, Annual General Meeting, May 15, 2025, at 13:30 China Standard Time. Location: The Company's Meeting Room, Dalian, Liaoning China Valuation Update With 7 Day Price Move • Apr 03
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥28.99, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 22x in the Chemicals industry in China. Total returns to shareholders of 344% over the past three years. Announcement • Mar 28
Dalian BIO-CHEM Company Limited to Report Q1, 2025 Results on Apr 25, 2025 Dalian BIO-CHEM Company Limited announced that they will report Q1, 2025 results on Apr 25, 2025 Valuation Update With 7 Day Price Move • Mar 07
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥36.00, the stock trades at a forward P/E ratio of 48x. Average forward P/E is 21x in the Chemicals industry in China. Total returns to shareholders of 491% over the past three years. Valuation Update With 7 Day Price Move • Feb 21
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to CN¥30.17, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 21x in the Chemicals industry in China. Total returns to shareholders of 439% over the past three years. Valuation Update With 7 Day Price Move • Jan 20
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥24.46, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 19x in the Chemicals industry in China. Total returns to shareholders of 341% over the past three years. New Risk • Dec 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (10% average weekly change). Announcement • Dec 27
Dalian BIO-CHEM Company Limited to Report Fiscal Year 2024 Results on Apr 25, 2025 Dalian BIO-CHEM Company Limited announced that they will report fiscal year 2024 results on Apr 25, 2025 Valuation Update With 7 Day Price Move • Nov 18
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥22.86, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 19x in the Chemicals industry in China. Total returns to shareholders of 256% over the past three years. Valuation Update With 7 Day Price Move • Oct 29
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥20.91, the stock trades at a trailing P/E ratio of 34.1x. Average trailing P/E is 35x in the Chemicals industry in China. Total returns to shareholders of 274% over the past three years. Announcement • Sep 30
Dalian BIO-CHEM Company Limited to Report Q3, 2024 Results on Oct 30, 2024 Dalian BIO-CHEM Company Limited announced that they will report Q3, 2024 results on Oct 30, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to CN¥15.64, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 160% over the past three years. Announcement • Jun 28
Dalian BIO-CHEM Company Limited to Report First Half, 2024 Results on Aug 29, 2024 Dalian BIO-CHEM Company Limited announced that they will report first half, 2024 results on Aug 29, 2024 Valuation Update With 7 Day Price Move • May 22
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥17.56, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 18x in the Chemicals industry in China. Total returns to shareholders of 84% over the past three years. Reported Earnings • Apr 27
First quarter 2024 earnings released: EPS: CN¥0.27 (vs CN¥0.21 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.27 (up from CN¥0.21 in 1Q 2023). Revenue: CN¥338.3m (up 31% from 1Q 2023). Net income: CN¥98.3m (up 35% from 1Q 2023). Profit margin: 29% (in line with 1Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 14% per year. Announcement • Apr 27
Dalian BIO-CHEM Company Limited, Annual General Meeting, May 16, 2024 Dalian BIO-CHEM Company Limited, Annual General Meeting, May 16, 2024, at 13:30 China Standard Time. Location: The Company's Meeting Room, Dalian, Liaoning China Announcement • Mar 30
Dalian BIO-CHEM Company Limited to Report Q1, 2024 Results on Apr 26, 2024 Dalian BIO-CHEM Company Limited announced that they will report Q1, 2024 results on Apr 26, 2024 Valuation Update With 7 Day Price Move • Mar 12
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥11.96, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 29x in the Chemicals industry in China. Total returns to shareholders of 24% over the past three years. New Risk • Feb 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.6% average weekly change). Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to CN¥8.78, the stock trades at a trailing P/E ratio of 8.9x. Average trailing P/E is 26x in the Chemicals industry in China. Negligible returns to shareholders over past three years. Announcement • Dec 30
Dalian BIO-CHEM Company Limited to Report Fiscal Year 2023 Results on Apr 26, 2024 Dalian BIO-CHEM Company Limited announced that they will report fiscal year 2023 results on Apr 26, 2024 Valuation Update With 7 Day Price Move • Nov 09
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥11.80, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 37x in the Chemicals industry in China. Total loss to shareholders of 3.6% over the past three years. Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.31 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.27 (down from CN¥0.31 in 3Q 2022). Revenue: CN¥277.8m (down 19% from 3Q 2022). Net income: CN¥93.1m (down 14% from 3Q 2022). Profit margin: 34% (up from 32% in 3Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Dalian BIO-CHEM Company Limited to Report Q3, 2023 Results on Oct 27, 2023 Dalian BIO-CHEM Company Limited announced that they will report Q3, 2023 results on Oct 27, 2023 Reported Earnings • Aug 29
Second quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.37 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.32 (down from CN¥0.37 in 2Q 2022). Revenue: CN¥315.2m (down 14% from 2Q 2022). Net income: CN¥117.2m (down 9.2% from 2Q 2022). Profit margin: 37% (up from 35% in 2Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Jun 28
Dalian BIO-CHEM Company Limited to Report First Half, 2023 Results on Aug 29, 2023 Dalian BIO-CHEM Company Limited announced that they will report first half, 2023 results on Aug 29, 2023 Reported Earnings • Apr 30
Full year 2022 earnings released: EPS: CN¥1.61 (vs CN¥1.00 in FY 2021) Full year 2022 results: EPS: CN¥1.61 (up from CN¥1.00 in FY 2021). Revenue: CN¥1.26b (up 25% from FY 2021). Net income: CN¥402.6m (up 61% from FY 2021). Profit margin: 32% (up from 25% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Buying Opportunity • Apr 10
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 11%. The fair value is estimated to be CN¥19.29, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 7.7%. Revenue is forecast to grow by 24% in 2 years. Earnings is forecast to grow by 8.0% in the next 2 years. Buying Opportunity • Dec 13
Now 22% undervalued Over the last 90 days, the stock is up 1.1%. The fair value is estimated to be CN¥21.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 7.7%. Revenue is forecast to grow by 21% in 2 years. Earnings is forecast to grow by 14% in the next 2 years. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). Independent Director Yongze Liu was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 30
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: EPS: CN¥0.43 (up from CN¥0.14 in 3Q 2021). Revenue: CN¥343.6m (up 59% from 3Q 2021). Net income: CN¥108.4m (up 193% from 3Q 2021). Profit margin: 32% (up from 17% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 26%. Earnings per share (EPS) also surpassed analyst estimates by 153%. Revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 17
Second quarter 2022 earnings released: EPS: CN¥0.52 (vs CN¥0.27 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.52 (up from CN¥0.27 in 2Q 2021). Revenue: CN¥366.4m (up 43% from 2Q 2021). Net income: CN¥129.1m (up 81% from 2Q 2021). Profit margin: 35% (up from 28% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 18%, compared to a 42% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 5 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Mar 16
Investor sentiment improved over the past week After last week's 22% share price gain to CN¥13.90, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 27x in the Chemicals industry in China. Total returns to shareholders of 6.3% over the past three years. Reported Earnings • Mar 10
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: CN¥0.96 (up from CN¥0.85 in FY 2020). Revenue: CN¥1.01b (up 34% from FY 2020). Net income: CN¥251.5m (up 13% from FY 2020). Profit margin: 25% (down from 30% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Nov 17
Investor sentiment improved over the past week After last week's 21% share price gain to CN¥14.35, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 19x in the Chemicals industry in China. Total returns to shareholders of 61% over the past three years. Reported Earnings • Nov 03
Third quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.19 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥216.8m (up 28% from 3Q 2020). Net income: CN¥37.0m (down 27% from 3Q 2020). Profit margin: 17% (down from 30% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 11% per year. Reported Earnings • Aug 24
Second quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.15 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥256.8m (up 30% from 2Q 2020). Net income: CN¥71.3m (up 88% from 2Q 2020). Profit margin: 28% (up from 19% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 25
First quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.34 in 1Q 2020) The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: CN¥218.4m (up 9.4% from 1Q 2020). Net income: CN¥51.8m (down 42% from 1Q 2020). Profit margin: 24% (down from 45% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 01
Full year 2020 earnings released: EPS CN¥0.85 (vs CN¥1.17 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥749.5m (down 14% from FY 2019). Net income: CN¥221.8m (down 28% from FY 2019). Profit margin: 30% (down from 35% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Jan 28
New 90-day low: CN¥14.62 The company is down 19% from its price of CN¥18.00 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 23% over the same period. Is New 90 Day High Low • Jan 11
New 90-day low: CN¥14.64 The company is down 20% from its price of CN¥18.24 on 13 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period. Valuation Update With 7 Day Price Move • Dec 24
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥14.88, the stock is trading at a trailing P/E ratio of 15.6x, down from the previous P/E ratio of 18.8x. This compares to an average P/E of 35x in the Chemicals industry in China. Total returns to shareholders over the past three years are 44%. Is New 90 Day High Low • Dec 20
New 90-day low: CN¥17.20 The company is down 4.0% from its price of CN¥17.91 on 21 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥251.4m, down 7.3% from the prior year. Total revenue was CN¥837.2m over the last 12 months, up 15% from the prior year. Announcement • Oct 28
Dalian BIO-CHEM Company Limited to Report Q3, 2020 Results on Oct 30, 2020 Dalian BIO-CHEM Company Limited announced that they will report Q3, 2020 results on Oct 30, 2020 Announcement • Jul 09
Dalian BIO-CHEM Company Limited to Report First Half, 2020 Results on Aug 25, 2020 Dalian BIO-CHEM Company Limited announced that they will report first half, 2020 results on Aug 25, 2020